Assessment of the therapeutic value of new medicines marketed in Australia

about

Assessment of the therapeutic value of new medicines marketed in Australia.Canadian status of "drugs to avoid" in 2017: a descriptive analysis

P2860

Q41107765-82238E15-6B28-41BA-BA4B-3C08ABE8D693 Q58697277-2F1C1BBD-F7BC-4C1E-BEB7-47E6A83926A2

P2860

Assessment of the therapeutic value of new medicines marketed in Australia

Item

http://www.wikidata.org/entity/Q37703341

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 13 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Assessment of the therapeutic value of new medicines marketed in Australia

@en

Assessment of the therapeutic value of new medicines marketed in Australia.

@nl

type

Item

label

Assessment of the therapeutic value of new medicines marketed in Australia

@en

Assessment of the therapeutic value of new medicines marketed in Australia.

@nl

prefLabel

Assessment of the therapeutic value of new medicines marketed in Australia

@en

Assessment of the therapeutic value of new medicines marketed in Australia.

@nl

P1476

Assessment of the therapeutic value of new medicines marketed in Australia

@en

P2093

Ng Huah Shin

http://www.w3.org/2001/XMLSchema#string

Pauline Vitre

http://www.w3.org/2001/XMLSchema#string

P2860

Superior efficacy of new medicines?

Toward a definition of pharmaceutical innovation.

Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003.

Prices for innovative pharmaceutical products that provide health gain: a comparison between Australia and the United States.

What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia.

How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers.

A review of quantitative risk-benefit methodologies for assessing drug safety and efficacy-report of the ISPOR risk-benefit management working group.

An update on the first decade of the European centralized procedure: how many innovative drugs?

P2888

2052-3211-6-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/2052-3211-6-2

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Agnes I. Vitry

P577

2013-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

257885198

http://www.w3.org/2001/XMLSchema#string

P6179

1023675734

http://www.w3.org/2001/XMLSchema#string

P698

24764537

http://www.w3.org/2001/XMLSchema#string

P921

Australia

P932

3987060

http://www.w3.org/2001/XMLSchema#string

Assessment of the therapeutic value of new medicines marketed in Australia

about

P2860

P2860

Assessment of the therapeutic value of new medicines marketed in Australia

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P478

P50

P577

P5875

P6179

P698

P921

P932